GU Cancers 2019 | Identifying predictive markers for checkpoint inhibitor response in kidney cancer

Tian Zhang

Tian Zhang, MD, of Duke Cancer Center, Durham, NC, discusses the role of sequencing in identifying genomic mutations that correlate with immunotherapy response in kidney cancer patients. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Zhang reports that results from sequencing can be used to help choose combination treatment options to pair with immunotherapy.

Share this video